Добірка наукової літератури з теми "Démence frontotemporale – diagnostic"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Démence frontotemporale – diagnostic".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Démence frontotemporale – diagnostic"
Trouvé, Magali, and Lionel Reinheimer. "Diagnostic différentiel entre schizophrénie et démence frontotemporale." L'information psychiatrique 87, no. 9 (2011): 725. http://dx.doi.org/10.3917/inpsy.8709.0725.
Повний текст джерелаTrouvé, Magali, and Lionel Reinheimer. "Diagnostic différentiel entre schizophrénie et démence frontotemporale." L'information psychiatrique Volume 87, no. 9 (November 1, 2011): 725–31. http://dx.doi.org/10.1684/ipe.2011.0858.
Повний текст джерелаFayemendy, P., N. Calmel, H. Sourisseau, G. Lautrette, P. M. Preux, P. Couratier, J. C. Desport, and P. Jésus. "État nutritionnel et métabolique au diagnostic et survie des patients atteints de sclérose latérale amyotrophique (SLA) avec démence frontotemporale versus patients atteints de SLA seule." Nutrition Clinique et Métabolisme 35, no. 1 (April 2021): 48. http://dx.doi.org/10.1016/j.nupar.2021.01.059.
Повний текст джерелаMadigand, J., and P. Lebain. "Complexité diagnostique d’un syndrome catatonique en psychiatrie et neurologie : à propos d’un cas." European Psychiatry 28, S2 (November 2013): 48–49. http://dx.doi.org/10.1016/j.eurpsy.2013.09.126.
Повний текст джерелаLebouvier, T., M. Bertoux, M. Leroy, F. Lebert, V. Deramecourt, and F. Pasquier. "Diagnostic positif et étiologique des démences frontotemporales." Pratique Neurologique - FMC 10, no. 2 (April 2019): 101–11. http://dx.doi.org/10.1016/j.praneu.2019.02.012.
Повний текст джерелаGaubert, Laura, Jean-Paul Niguet, Emilie Skrobala, and Florence Pasquier. "Pourquoi le diagnostic des démences frontotemporales est-il si tardif ?" Revue Neurologique 177 (April 2021): S8. http://dx.doi.org/10.1016/j.neurol.2021.02.092.
Повний текст джерелаLehmann, Sylvain, Constance Delaby, and Stéphanie Miot. "Les neurofilaments (NfL) comme biomarqueur sanguin pour différentier démence frontotemporale (DFT) et diagnostics psychiatriques primaires (DPP)." Revue Neurologique 179 (April 2023): S69. http://dx.doi.org/10.1016/j.neurol.2023.01.413.
Повний текст джерелаHanon, C. "Le syndrome de Diogène : du mythe à la pathologie." European Psychiatry 28, S2 (November 2013): 79. http://dx.doi.org/10.1016/j.eurpsy.2013.09.211.
Повний текст джерелаДисертації з теми "Démence frontotemporale – diagnostic"
Fournier, Emmanuel. "Syndromes dépressifs des personnes âgées et altération cognitive, apport de la tomoscintigraphie d'émission monophotonique à l'HMPAO-Tc 99m : étude préliminaire." Bordeaux 2, 2001. http://www.theses.fr/2001BOR2M011.
Повний текст джерелаLeroy, Mélanie. "Contribution des bases de données de soin courant à l’amélioration du diagnostic et du pronostic de la maladie d’Alzheimer et des dégénérescences lobaires frontotemporales." Electronic Thesis or Diss., Université de Lille (2018-2021), 2021. http://www.theses.fr/2021LILUS026.
Повний текст джерелаBiomarkers, whether cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), or positional emission tomography (PET), have acquired a prominent place in the diagnostic process of a cognitive disorder. They are an integral part of the diagnostic criteria for Alzheimer's disease (AD) and its main differential diagnosis, frontotemporal dementia (FTD). In 2021, however, histological analysis, where pathological changes are observed directly on tissues, often remains the only method allowing a diagnosis of certainty.In 1992, the Lille Memory Resource and Research Center (CMRR) set up a network of memory consultations in the Nord Pas-de-Calais region. In addition to standardizing care, it has set up a database that now includes over 120,000 patients. Based on this large active file, our work consisted in studying the clinical and biochemical characteristics of AD and FTD patients on different scales (rare but perfectly characterized cases of clinicopathological correlations, monocentric cohorts of patients having undergone lumbar puncture, regional or international cohorts).Our first study focused on the correlations between the biochemical profile of cerebrospinal fluid (CSF) and post-mortem findings. We were able to show that amyloid and tau biomarkers are less sensitive to the corresponding pathologies when these are not yet fully developed in the cortex, leading to incomplete detection of patients with AD-related neuropathological changes.We subsequently focused on AD patients with pathological tau and pTau biomarkers in the CSF, pathological Aβ42/Aβ40 ratio, but normal Aβ42 levels. We showed that the cognitive, morphological, and functional profile of patients with AD and normal Aβ42 does not differ from those with pathological Aβ42.In the setting of FTD, CSF biomarkers are used to rule out a possible diagnosis of AD. Nevertheless, if this is the case, a whole spectrum of pathology remains possible as FTD is so heterogeneous. There are currently few established phenotype-pathology correlations, which, at the dawn of the development of a targeted treatment, may represent a loss of chance for these patients. We wished to constitute a multicentric cohort of patients with confirmed post-mortem FTD, in order to improve clinicopathological correlations. This preliminary work demonstrates the complexity of the FTD spectrum, with many phenotypic and histological overlaps.In addition to this study of gold standard FTD patients, we wished to consider the entire FTD active file of the Nord Pas-de-Calais memory consultation network. Although this disease is rare, the pooling of data within the network allowed us to reach a large number of patients. This work allowed us to demonstrate that FTD differs from AD, both in terms of initial characteristics, speed of progression and treatment. Despite the use of the latest clinical criteria, these pathologies remain under-diagnosed and should no longer be considered as limited to young subjects.Although each memory center, individually, is in a position to contribute to the advancement of science and to help better understand neurodegenerative diseases, it seems obvious at this time that the pooling of health data is indispensable. Within the framework of the European Human Brain Project, we have worked on the implementation of a federated data analysis tool. The Medical Informatics Platform allows complex analyses to be carried out from geographically distant databases, thus avoiding transfers and the risk of health data leaks between research centers.Data from routine care is abundant and contains a lot of information. It is up to us to make the most of it to advance our understanding of neurocognitive diseases, a challenge for the years to come